AI Article Synopsis

  • Sigma-1 receptors are linked to learning and motivation, and PD144418 is a σ receptor antagonist that reduces cocaine-induced activity without impacting normal movement in mice.
  • PD144418 decreases the motivation to work for food in male rats without affecting their appetite, but it’s unclear how it influences feeding motivation during energy deficit states or in female rats.
  • In a study, PD144418 reduced the effort to obtain food in both male and female rats when they were not hungry, but its effects varied in females during food deprivation.

Article Abstract

Sigma-1 (σ) receptors have been investigated for their involvement in learning, rewarding and motivational processes. PD144418, a σ receptor antagonist, has been found to produce a dose-dependent attenuation of locomotor activity induced by cocaine, and by itself, does not suppress basal locomotor activity in mice. Moreover, PD144418 decreases the motivational effort of a food-reinforced behavior in male rats, without altering appetite or food palatability. It remains unknown whether the PD144418 can alter the motivational effort of a food-reinforced behavior in response to altered energy homeostasis, as is the case under 24 -h food deprivation. Additionally, while the previous experiments indicate effects in male rats, there has been no research examining the effects of PD144418, or any other σ receptor antagonist, on motivational aspects of feeding in females. The present study examined the effects of PD144418 on motivational aspects of feeding in male and female rats using an operant task under sated or food deprived conditions. Results indicated that when animals are sated, at the highest dose (10 μmol/kg), under a progressive ratio (PR) reinforcement schedule, PD144418 significantly attenuated the breakpoint and the number of active lever responses for sucrose pellets in both males and females. When animals are in a state of energy deficit, as is the case following 24-hr food deprivation, PD144418 does not alter motivationally driven operant responding as measured by the breakpoint in either sex but does alter the number of earned reinforcers responses in females.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbr.2019.112087DOI Listing

Publication Analysis

Top Keywords

receptor antagonist
12
pd144418
8
pd144418 receptor
8
locomotor activity
8
motivational effort
8
effort food-reinforced
8
food-reinforced behavior
8
male rats
8
pd144418 alter
8
food deprivation
8

Similar Publications

Article Synopsis
  • The negative symptoms of schizophrenia, like lack of emotion and motivation, are hard to treat and significantly impact daily functioning.
  • This review highlights current research on treatment options for these symptoms, categorizing them into different types and evaluating various assessment scales.
  • Although no treatments are conclusively proven as the best for these symptoms, some off-label and investigational medications show promise, including cariprazine and memantine, and further research is needed to explore new therapeutic possibilities.
View Article and Find Full Text PDF

[A Review of progresses in research on delayed resistance to EGFR-TKI by Traditional Chinese medicine via inhibiting cancer stem cells properties].

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi

January 2025

Department of Integrated Traditional Chinese and Western Medicine, Shandong First Medical University Affiliated Cancer Hospital, Jinan 250117, China. *Corresponding author, E-mail:

It has been popular and challenging to undertake researches on the delay of acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). As key cells for tumor initiation, cancer stem cells (CSC) play an important role in the process of resistance to EGFR-TKI. Although preliminary studies found that traditional Chinese medicine (TCM) could inhibit CSC properties and delay EGFR-TKI resistance, the specific molecular mechanism remains unclear.

View Article and Find Full Text PDF
Article Synopsis
  • The study explores the effectiveness and safety of combining nivolumab, an immunotherapy drug, with chemotherapy in patients with a specific type of metastatic gastric cancer co-expressing FGFR2 and PD-L1.
  • A total of 23 patients were treated, showing a 1-year progression-free survival (PFS) rate of 30.4% and a median overall survival (OS) of 15.1 months, though the primary endpoint of improved 1-year PFS was not achieved.
  • The results highlight the need for future research on patient selection and potential combination therapies to enhance treatment outcomes in this patient population.
View Article and Find Full Text PDF

Background: Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, leading to fluctuating muscle weakness. While many patients respond well to standard immunosuppression, a substantial subgroup faces ongoing disease activity. Emerging treatments such as complement factor C5 inhibition (C5IT) and neonatal Fc receptor (FcRn) antagonism hold promise for these patients.

View Article and Find Full Text PDF

Background: We report our experience of patients with generalised myasthenia gravis (gMG) treated with efgartigimod, an neonatal Fc receptor antagonist, under the Early Access to Medicine Scheme (EAMS) in the UK.

Methods: Data from all UK patients treated with efgartigimod under the EAMS July 2022 to July 2023 were collected retrospectively. Efgartigimod was administered as per the ADAPT protocol (consisting of a treatment cycle of four infusions at weekly intervals with further cycles given according to clinical need).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!